<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000546734">
  <TermName>tyrosine kinase inhibitor BIBF 1120</TermName>
  <TermPronunciation>(TY-ruh-seen KY-nays in-HIH-bih-ter...)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of some types of cancer. Tyrosine kinase inhibitor BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called BIBF 1120.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000718790" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tyrosine kinase inhibitor BIBF 1120&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000718791" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inhibidor de tirosina–cinasas BIBF 1120&quot;" language="es" id="_4"/>
  <SpanishTermName>inhibidor de tirosina–cinasas BIBF 1120</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El inhibidor de tirosina–cinasas BIBF 1120 bloquea las enzimas que las células necesitan para multiplicarse y es posible que prevenga la formación de vasos sanguíneos  nuevos que los tumores necesitan para crecer. Es un tipo de antiangiogénico y de inhibidor de tirosina–cinasas. También se llama BIBF 1120.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2007-05-04</DateFirstPublished>
  <DateLastModified>2009-04-21</DateLastModified>
</GlossaryTerm>
